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Abstract
Aim: There is no general consensus on the optimal treatment for prostate cancer (PC) patients with intrapelvic
nodal oligorecurrences after radical prostatectomy. Besides androgen deprivation therapy (ADT) as standard of care,
both elective nodal radiotherapy (ENRT) and stereotactic body radiotherapy (SBRT) as well as salvage lymph node
dissection (sLND) are common treatment options. The aim of our study was to assess decision making and practice
patterns for salvage radiotherapy (RT) in this setting.
Methods: Treatment recommendations from 14 Swiss radiation oncology centers were collected and converted
into decision trees. An iterative process using the objective consensus methodology was applied to assess
differences and consensus.
Results: PSMA PET/CT was recommended by 93% of the centers as restaging modality. For unfit patients defined by
age, comorbidities or low performance status, androgen deprivation therapy (ADT) alone was recommended by more
than 70%. For fit patients with unfavorable tumor characteristics such as short prostate-specific antigen (PSA) doubling
time or initial high-risk disease, the majority of the centers (57–71%) recommended ENRT + ADT for 1–4 lesions. For fit
patients with favorable tumor characteristics, there were low levels of consensus and a wide variety of
recommendations. For 1–4 nodal lesions, focal SBRT was offered by 64% of the centers, most commonly as a 5-fraction
course.
Conclusions: As an alternative to ADT, ENRT or SBRT for pelvic nodal oligorecurrences of PC are commonly offered to
selected patients, with large treatment variations between centers. The exact number of lymph nodes had a major
impact on treatment selection.
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Background
Regional nodal recurrence of prostate cancer (PC) limited
to the pelvis (pelvic oligorecurrences) after curative local
therapies such as radical prostatectomy (RP) or primary
radiotherapy (RT) is an emerging clinical scenario. In part,
this may be explained by the broad implementation of
novel metabolic imaging strategies such as choline and
prostate specific membrane antigen (PSMA) PET-CT in
the last years [1–3]. These new imaging modalities have
improved both sensitivity and specificity to detect the site
of tumor recurrence in case of rising prostate-specific
antigen (PSA) leading to an increased utilization of
metastasis-directed approaches. Nevertheless, metastasis-
directed therapies (MDT) such as stereotactic body radio-
therapy (SBRT), salvage lymph node dissection (sLND) or
elective nodal radiotherapy (ENRT) to the pelvis remain a
controversial issue as an addition or replacement therapy
modality to androgen deprivation therapy (ADT) [2].
Current PC guidelines such as the European Association
of Urology (EAU) and European Society of Radiation
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Oncology (ESTRO) Guidelines [4] do not specifically ad-
dress pelvic oligorecurrences, as there is very limited data
from prospective trials [2, 5, 6]. In contrast, there is an in-
creasing number of retrospective studies suggesting that
patients with pelvic oligorecurrences may benefit from
MDT [1, 7, 8]. Optimal patient selection for loco-regional
therapy based on the number of nodal recurrences and
other risk factors is currently unclear.
Based on similar analyses among radiation oncology
centers on radiotherapy for primary PC and for macro-
scopic local recurrences [9, 10], the aim of this study
was to assess current patterns of practice for pelvic
nodal oligorecurrences of PC after RP among centers
within a similar environment. The Swiss centers that
were analyzed are all within the same environment char-
acterized by universal healthcare coverage, modern
equipment, uncomplicated reimbursement and no sig-
nificant logistical or transport obstacles for patients.
Methods
We contacted all Swiss university hospitals (n = 5) and
radiation oncology centers (n = 9) which had partici-
pated in the Swiss Group for Clinical Cancer Research
(SAKK) prospective study 09/10 on dose-escalated sal-
vage radiotherapy for biochemically recurrent disease
[11] in congruence with a previous survey [9].
Representatives from fourteen centers were asked to
provide their institutional treatment recommendations
in any format (e.g. figure, text, diagram), which were
consequently converted into decision trees in a bilat-
eral iterative process between the coordinating center
and the participants (objective consensus method-
ology) as previously described [9, 12, 13]. Specific deci-
sion criteria or cut-off values were not provided to
avoid bias. Additionally, the representatives were asked
to define target volume definitions and planning target
volume (PTV) margins, radiation dose prescription
and describe their use of concomitant ADT. Institu-
tional treatment recommendations were collected as
free unrestricted text until June 2019. Consequently,
they were converted into decision trees (by CP and
PMP) and verified in a bilateral process by the individ-
ual participants. In order to improve comparability of
treatment recommendations, standardized common
decision criteria for tumor characteristics and patient
fitness were established and accepted by all participat-
ing centers [12]. The initial open-question survey
which was sent to the participating centers can be
found in the Additional file 1.
The resulting treatment algorithms were compared
semi-automatically and analyzed for consensus and dif-
ferences [13]. A representative treatment decision tree of
a participating center is shown in Fig. 1.
Results
Fourteen Swiss radiation oncology centers were con-
tacted. All centers returned the survey and the review of
the center-specific treatment algorithms were confirmed
in June 2019.
Decision criteria from all centers were collected and
merged with the agreement of all participants into the
criteria “patient fitness” and “favorable vs. unfavorable
tumor characteristics” in order to facilitate the compar-
ability of decision algorithms [12]: Patient fitness was de-
fined by the majority of centers by age (64%) and
performance status (57%) as well as by comorbidities
(64%). However, specific cut-off values or exclusion cri-
teria for these factors were not provided and the final
decision on patient fitness was left to the discretion of
the treating physician in all centers. Tumor characteris-
tics considered unfavorable and relevant for treatment
decisions were inconsistently defined among the centers
and are summarized in Table 1.
The highest level of consensus for the use of any RT
(71%) was obtained for the use of pelvic RT and ADT in
fit patients with unfavorable tumor characteristics and
two to three lymph node recurrences (Fig. 2). There was
a high level of consensus for the use of ADT without RT
in case of six or more nodal recurrences in fit patient or
in two or more nodal recurrences in unfit patients.
Fit patients with favorable tumor characteristics hav-
ing 1 or 4 lymph node recurrences lead to the most
heterogeneous recommendations. The variety of treat-
ment recommendations for these two scenarios are
shown in Table 2.
Treatment specifications are summarized in Table 3.
PSMA PET/CT was recommended by all but one center
as the standard restaging imaging modality (93% of the
centers). An additional multiparametric pelvic magnetic
resonance imaging (MRI) was recommended by 64% of
the centers.
Median dose recommendation for ENRT was 50 Gy,
with inclusion of the prostate bed in 58% of the centers
(n = 7). SBRT for pelvic lymph node recurrences was
most commonly recommended in a five-fraction course
with daily doses of 6 to 8 Gy.
The majority of centers (57%) recommended the
addition of concomitant ADT for a duration of six
months and one center for nine months (7%). Twenty-
one percent of the centers (n = 4) recommended ADT in
the presence of risk factors for up to 24months. One
center left the duration of the ADT to the discretion of
the referring urologist.
Discussion
A proportion of patients with prostate cancer develop
local, regional or distant recurrence after curative local
treatment, which is increasingly detected due to novel
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imaging modalities such as choline or PSMA PET-CT
[1, 3]. PC patients with pelvic oligorecurrences show a
more favorable prognosis than patients with recurrent
visceral or bone metastases [1]. However, this circum-
stance is not addressed in current guidelines for stage IV
prostate cancer [4]. Although high-level evidence for
local therapies in oligorecurrent prostate cancer is still
lacking, both MDT such as SBRT or sLND and ENRT
are increasingly in use [2], mainly based on suggestive data
from retrospective series [14]. Additionally, there is in-
creasing evidence on the benefits of MDT in oligometa-
static disease in other tumor entities: The recently
published randomized phase II SABR-COMET trial dem-
onstrated an increased OS (41 vs. 28months) for SBRT in
addition to standard systemic therapy in oligometastatic
patients with different primaries, also including prostate
cancer [15]. In stage IV non-small cell lung cancer, two
randomized phase II trials reported for local therapy to
oligometastatic sites, including SBRT, an improved PFS as
well as improved OS in one of the trials [16, 17].
Our analysis shows that loco-regional treatment is com-
monly offered to patients with intrapelvic oligorecurrent
prostate cancer, but there is considerable variety in the
choice of the specific treatment modality. We would
expect that the rather homogeneous environment of the
healthcare system in Switzerland would not cause differ-
ences in treatment recommendations due to the lack of
resources, insurance coverage or available technology [18].
With respect to imaging modalities, all centers rec-
ommended choline or PSMA PET-CT which is cur-
rently common practice in case of biochemical
recurrence after primary curative therapy of prostate
cancer [2, 19]. A recent study on the impact of PSMA
PET-CT on treatment decisions for recurrent prostate
cancer showed that patient management changed in
60% with a substantial increase in metastasis-directed
treatment and a reduction in the use of systemic ther-
apy [20]. These findings are in line with a prospective
study investigating the impact of PSMA PET-CT on the
management of patients with a biochemical recurrence
of prostate cancer. PSMA PET-CT changed manage-
ment in 54 of 101 patients (53%). PSMA PET-CTs in a
series of 125 patients detected recurrences, which
would be missed by standard radiation fields to the
prostate bed in every third patient [21].
In “unfit” patients defined by age, performance status
or comorbidities, more than two thirds of the centers
recommended ADT alone without further local therapy
irrespective of the number of lymph node recurrences.
Also, 79% of the centers recommended ADT alone for
more than five lymph node recurrences irrespective of
other tumor characteristics. However, we did not include
the recommended time point of the start of ADT (im-
mediate versus delayed) in our survey, as this treatment
decision is most commonly taken by the responsible ur-
ologist or medical oncologist in Switzerland. For patients
with biochemical recurrence of prostate cancer, delaying
ADT is a valuable option. The authors believe this is es-
pecially the case when rapid disease progression is not
expected and in cases of severe comorbidities potentially
Fig. 1 Representative decision tree from a single participating center. LN, lymph node; RT, radiotherapy; SBRT, stereotactic body radiotherapy;
ADT, androgen deprivation therapy
Table 1 Tumor characteristics named as relevant for treatment
decision
Characteristic % (number of centers)
PSA doubling time 57% (n = 8)
Initial high-risk disease 36% (n = 5)
PSA level at recurrence 29% (n = 4)
Size of lymph node recurrence 14% (n = 2)
Interval since RP 14% (n = 2)
Multiple factors were named by some centers. PSA, prostate-specific antigen.
RP, radical prostatectomy.
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complicating earlier treatment, as ADT may worsen the
quality of life and may aggravate cardiovascular morbid-
ity [4]. This being said, optimal patient selection remains
a challenge.
Three to five lesions are often considered the upper
limit of oligometastatic disease that may benefit from
additional local treatment [2]. In the postoperative set-
ting of node positive (pN1) prostate cancer, Abdollah
et al. showed in a large retrospective analysis that adju-
vant radiotherapy was associated with better survival
only in patients with up to four lymph nodes [22].
In summary, ADT with or without MDT was recom-
mended by the majority of centers for pelvic oligorecur-
rences according to current guidelines for stage IV
disease [4]. However, for fit patients with favorable
tumor characteristics and a single lymph node recur-
rence, 50% of the centers recommended MDT (mainly
SBRT) without concomitant ADT. For unfit patients,
SBRT alone for single lymph node recurrences was an
option for 29% of the centers. This strategy may be sup-
ported by the recent randomized phase II STOMP trial,
which showed that MDT in oligorecurrent prostate can-
cer increased the median ADT-free survival from 13
months to 21months [5], although one should note that
in our analysis ADT was typically recommended concur-
rently. Likewise, the Australian phase I POPSTAR trial
showed that single fraction SBRT is safe and leads to a
2-year freedom of ADT in 48% of the patients [6]. While
Fig. 2 Mode decision tree for intra-pelvic lymph node recurrences of prostate cancer after RPE. LN, lymph node; RT, radiotherapy; SBRT,
stereotactic body radiotherapy; ADT, androgen deprivation therapy
Table 2 Treatment recommendations for clinical scenarios without consensus
Scenario without consensus Recommended treatment options (number of centers)
Single lymph node recurrence
Fit patient
Favorable tumor characteristics
43% SBRT (n = 6)
29% Pelvic RT + ADT (n = 4)
7% SBRT + ADT (n = 1)
7% SBRT or pelvic RT (n = 1)
7% SBRT +/−ADT or pelvic RT + ADT (n = 1)
7% Surgery and/or pelvic RT + ADT (n = 1)
Four lymph node recurrences
Fit patient
Favorable tumor characteristics
43% ADT (n = 6)
36% Pelvic RT + ADT (n = 5)
14% SBRT (n = 2)
7% Pelvic RT (n = 1)
RT, radiotherapy; SBRT, stereotactic body radiotherapy; ADT, androgen deprivation therapy.
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this finding seems reproducible, in many cases the right
timing to start ADT remains unclear.
Interestingly, one radiation oncology center recom-
mended sLND as a treatment option for a single lymph
node recurrence in fit patients with favorable tumor
characteristics as alternative to SBRT [23].
In contrast, for patients with unfavorable tumor char-
acteristics, more than half of the centers recommended
ENRT plus ADT.
Currently it remains unclear whether MDT such as
sLND or SBRT provide sufficient control for intrapelvic
recurrences of prostate cancer. Although direct compara-
tive data is scarce, there is a trend for longer progression-
free survival (PFS) rates in patients receiving ENRT of the
pelvis [24] compared to focal SBRT [25, 26] or sLND
alone [23]. Rischke et al. [27] reported on a series of 93
patients with pelvic lymph node recurrences which re-
ceived sLND with or without ENRT. Five-year biochem-
ical PFS rates were significantly higher in patients
receiving additional RT (34.3% vs. 15.4%) [27]. Similarly,
Lepinoy et al. compared 35 patients receiving SBRT to 27
patients receiving ENRT for nodal oligorecurrences from
prostate cancer [28]. Three-year failure rate was signifi-
cantly higher after MDT (88.3% vs. 55.3%) without
increased late toxicity in the ENRT group [28]. In sum-
mary, the available retrospective series on ENRT versus
SBRT report improved PFS for ENRT, although there is
the potential risk of increased toxicity by ENRT compared
to SBRT [29].
Based on this preliminary evidence, it appears reason-
able that most centers recommended ENRT in patients
with unfavorable tumor characteristics with a higher risk
of disease progression. MDT (SBRT or sLND) and
ENRT (exclusive or adjuvant after sLND) for three or
less oligorecurrent pelvic lymph node recurrences of
prostate cancer in addition to short-term ADT are cur-
rently prospectively compared in the ongoing random-
ized phase II STORM trial (NCT03569241).
Additionally, the GETUG OLIGOPELVIS P07 trial
(NCT02274779) will prospectively evaluate the use of
high-dose ENRT plus ADT in oligorecurrent prostate
cancer with up to five lymph nodes [30].
Patient selection for MDT or ENRT remains a critical
issue. In our survey, most experts used PSA-related fac-
tors such as PSA level, PSA doubling time and time
from RP to biochemical progression as clinical surrogate
parameters for adverse tumor biology as commonly
done in other disease stages in prostate cancer [31, 32].
Also, the initial risk group defined by the T category of
the primary tumor, the histological Gleason score and
the initial PSA [31] was explicitly considered by more
than one third of the centers. For patients with these un-
favorable tumor characteristics, the majority of the cen-
ters recommended more commonly ENRT combined
Table 3 Treatment specifications
Factor Recommendations
Recommended Imaging before therapeutic decision 93% PSMA PET/CT
64% pelvic multiparametric MRI
further: bone scan, PSMA-PET MRI, choline PET (1 center each)
Dose to elective pelvic lymph nodes (ENRT) Median dose 50 Gy (range, 45–54 Gy) in 1.8–2 Gy/fraction
No pelvic RT recommended by 14%
Prostate bed RT Always included by 58% of the centers using pelvic RT
Median dose 66 Gy (range, 64–70 Gy)
Dose for lymph node boost for pelvic RT SIB in 75%, median dose 66 Gy (range 57.5–70 Gy, single dose 2–2.5 Gy)
SBRT boost in 25% (2 × 5 Gy)
SBRT* 29% 3-fraction course (SD 10–15 Gy)
43% 5-fraction course (SD 6–8 Gy)
14% > 10 fraction course (SD 3.5 Gy)
36% no primary SBRT
Margins SBRT CTV, median 0 mm (range, 0–5 mm)
PTV, median 5 mm (range, 3–5 mm)
Recommendation for concomitant ADT standard duration 57% six months, 7% nine months
21% in the presence of risk factors 6–24months
29% no concomitant ADT (in addition to SBRT)
* for SBRT, some center provided more than one fractionation schedule
CTV, clinical target volume; PSMA, prostate specific membrane antigen; PTV, planning target volume; RT, radiotherapy; SIB, simultaneous integrated boost; SBRT,
stereotactic body radiotherapy; SD, single dose.
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with ADT instead of MDT alone. Patients with these
adverse features are considered at a higher risk for
rapid loco-regional or systemic progression. Tran et al.
showed that oligorecurrent patients with five or less
nodal metastases had a significantly reduced 5-year
PFS (36.8% vs. 63.6%) in case of a PSA doubling time
of less than 3 months even when ENRT plus ADT was
used [24].
Additional translational research is needed in order to
improve our understanding of tumor biology of oligore-
current prostate cancer and to optimize risk stratifica-
tion and patient selection for each of the available
salvage therapies [2].
Our study had some inherent limitations. While we as-
sume that we captured a representative picture of the
current patterns of practice, not every patient may be
treated according to the collected algorithms, as treat-
ment decisions in oligometastatic disease are commonly
a result of an interdisciplinary discussion of the radiation
oncologist with the referring urologist or medical on-
cologist under consideration of the patients’ individual
preferences and risks. Additionally, we cannot exclude
that other factors may influence decisions, which have
not been considered in our analysis [33]. Also, our sur-
vey may have a “specialty bias”, as radiation oncologists
like other specialists tend to recommend their own treat-
ment options more frequently [34, 35].
Conclusions
In conclusion, the use of MDT strategies like SBRT and
ENRT has a high acceptance among radiation oncolo-
gists and are commonly recommended for PC patients
with pelvic oligorecurrences outside of clinical studies.
However, treatment recommendations are very hetero-
geneous among centers, without a clear consensus. The
exact number of lymph nodes was a very influential de-
cision criterion in treatment selection. Ongoing pro-
spective trials will hopefully provide further answers to
open questions, and improve the evidence on the best
treatment modality for oligorecurrent PC patients.
Additional file
Additional file 1. Initial open-question survey which was sent to the
participating centers.
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